Free Trial
NASDAQ:MGX

Metagenomi (MGX) Stock Price, News & Analysis

Metagenomi logo
$1.56 -0.05 (-2.80%)
As of 03:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Metagenomi Stock (NASDAQ:MGX)

Key Stats

Today's Range
$1.54
$1.64
50-Day Range
$1.26
$2.17
52-Week Range
$1.23
$8.17
Volume
273,406 shs
Average Volume
773,643 shs
Market Capitalization
$58.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.75
Consensus Rating
Buy

Company Overview

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Metagenomi Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

MGX MarketRank™: 

Metagenomi scored higher than 29% of companies evaluated by MarketBeat, and ranked 666th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Metagenomi has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Metagenomi has only been the subject of 2 research reports in the past 90 days.

  • Read more about Metagenomi's stock forecast and price target.
  • Earnings Growth

    Earnings for Metagenomi are expected to decrease in the coming year, from ($2.46) to ($2.52) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Metagenomi is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Metagenomi is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Metagenomi's valuation and earnings.
  • Percentage of Shares Shorted

    12.67% of the float of Metagenomi has been sold short.
  • Short Interest Ratio / Days to Cover

    Metagenomi has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Metagenomi has recently increased by 3.37%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Metagenomi does not currently pay a dividend.

  • Dividend Growth

    Metagenomi does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.67% of the float of Metagenomi has been sold short.
  • Short Interest Ratio / Days to Cover

    Metagenomi has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Metagenomi has recently increased by 3.37%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Metagenomi has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Metagenomi this week, compared to 6 articles on an average week.
  • Search Interest

    Only 4 people have searched for MGX on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Metagenomi to their MarketBeat watchlist in the last 30 days.
Receive MGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Metagenomi and its competitors with MarketBeat's FREE daily newsletter.

MGX Stock News Headlines

Metagenomi to Present at Upcoming Scientific Meetings
Comparing Metagenomi (MGX) & Its Peers
Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
Metagenomi (MGX) vs. Its Peers Head to Head Analysis
Metagenomi (MGX) vs. Its Competitors Financial Analysis
Metagenomi Leads The Charge With These 3 Penny Stocks
Metagenomi price target lowered to $7 from $14 at H.C. Wainwright
See More Headlines

MGX Stock Analysis - Frequently Asked Questions

Metagenomi's stock was trading at $3.61 at the beginning of 2025. Since then, MGX shares have decreased by 56.6% and is now trading at $1.5650.
View the best growth stocks for 2025 here
.

Metagenomi, Inc. (NASDAQ:MGX) announced its quarterly earnings data on Monday, March, 17th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by $0.01. The firm had revenue of $9.61 million for the quarter, compared to the consensus estimate of $13.18 million. Metagenomi had a negative net margin of 134.27% and a negative trailing twelve-month return on equity of 43.23%.

Metagenomi (MGX) raised $94 million in an initial public offering (IPO) on Friday, February 9th 2024. The company issued 6,250,000 shares at a price of $15.00 per share.

Top institutional investors of Metagenomi include Bank of New York Mellon Corp (0.13%) and Fortitude Advisory Group L.L.C. (0.10%). Insiders that own company stock include Holdings A/S Novo and Pamela Wapnick.
View institutional ownership trends
.

Shares of MGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Metagenomi investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
3/17/2025
Today
5/05/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MGX
Previous Symbol
NASDAQ:MGX
Fax
N/A
Employees
236
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.75
High Stock Price Target
$20.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+816.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-68,250,000.00
Net Margins
-134.27%
Pretax Margin
-137.13%

Debt

Sales & Book Value

Annual Sales
$52.30 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$60.19 million
Optionable
N/A
Beta
-0.65
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:MGX) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners